We report the case of a 10-year-old boy with molecular relapse of CML following unrelated donor BMT who developed fatal grade 4 acute GVHD of the gut and liver following one antigen-mismatched donor lymphocyte infusion. Previous experience of donor lymphocyte infusion in the HLA-mismatched setting is reviewed and the role of adoptive immunotherapy in this situation is discussed. Bone Marrow Transplantation (2001) 28, 623-625. Keywords: HLA-mismatched; donor lymphocyte infusion; graft-versus-host disease
In the absence of a fully HLA-matched donor, haemopoietic stem cell transplantation from an HLA-mismatched donor may be curative for leukaemia and, given the lack of donor availability, there is increasing interest in stem cell transplantation across MHC barriers. [1] [2] [3] In some leukaemias donor lymphocyte infusions (DLI) are an effective therapy for relapse after allogeneic stem cell transplantation. 4 However, the safety and efficacy of DLI in the HLA-mismatched setting has not been determined. We report the case of a 10-year-old boy with molecular relapse of CML following unrelated donor BMT who developed fatal grade 4 acute GVHD of the gut and liver following one antigenmismatched DLI and discuss the role of DLI in the HLAmismatched setting.
Case report
An 8-year-old boy presented in March 1997 with abdominal pain secondary to massive splenomegaly, a peripheral leucocyte count of 228 ϫ 10 9 /l and a platelet count of 1340 ϫ 10 9 /l. Blood film and bone marrow appearances were of chronic myeloid leukaemia in chronic phase and bone marrow cytogenetics confirmed the presence of the Philadelphia chromosome in 19 out of 20 metaphases examined.
He was initially treated with hydroxyurea, with reduction in his splenomegaly and good control of his peripheral counts.
The patient had no HLA-identical sibling and no fully matched unrelated donors. Nonetheless, in view of his age, it was felt that bone marrow transplantation from an unrelated donor offered the best chance of long-term survival. Therefore in February 1999, he received an unrelated donor bone marrow transplant from a class 1 single locus-mismatched female donor with conventional cyclophosphamide 120 mg/kg/TBI 1440 cGy (in eight fractions) conditioning. The graft was T cell-depleted in vitro with Campath 1M and 5 ϫ 10 Both patient and donor were CMV negative. Graftversus-host disease prophylaxis was cyclosporin and 'short' methotrexate.
The post-transplant course was relatively uncomplicated apart from two episodes of febrile neutropenia and grade I skin GVHD. The patient was discharged on day 90, at which time XY FISH analysis demonstrated good engraftment with 100% donor myeloid cells and 95% donor mononuclear cells in the peripheral blood. However, he retained his splenomegaly and remained molecularly positive for BCR-ABL in the peripheral blood by quantitative RT-PCR with a BCR-ABL/ABL ratio of 6% at 4 months post BMT. Cyclosporin was therefore tailed, with initial improvement in his BCR-ABL/ABL ratio to 0.1%, although he remained molecularly positive. However, 7 months post transplant, his transcript level began rising again with a BCR-ABL/ABL ratio of 1% on two consecutive occasions, fulfilling the criteria for molecular relapse described by Cross et al. 5 Additionally, XY FISH analysis demonstrated an increasing host contribution to haemopoiesis, with 49% donor mononuclear cells and 67% donor myeloid cells in the peripheral blood. He was therefore treated with a low dose of donor lymphocytes (10 6 CD3-positive cells per kg) according to the escalating dose protocol described by Dazzi et al. 6 Four weeks later the patient developed diarrhoea and vomiting in association with a transient erythematous rash. He subsequently developed progressive hepatosplenome-galy and jaundice. Examination at that time showed him to be unwell, lethargic, jaundiced, with a low-grade fever, some cervical lymphadenopathy and a faint erythematous GVHD skin rash, as well as 5-6 cm hepatosplenomegaly. Blood counts showed him to be cytopenic with a white count of 0.47 ϫ 10 9 /l and platelets of 81 ϫ 10 9 /l. His LFTs were markedly deranged in a hepatitic pattern (bilirubin 149 m, ALT 393 U/l, ALP 347 U/l). PCR from the blood and bone marrow for CMV, adenovirus, parvovirus, hepatitis C and HHV6 were all negative, as was his hepatitis B surface antigen and hepatitis C IgM antibody tests. PCR for EBV in the blood was positive. An abdominal ultrasound showed hepatomegaly with no focal lesions and no biliary dilatation with normal portal and hepatic flows. A bone marrow aspirate was hypocellular with reduction in all three lineages. A skin biopsy was consistent with mild GVHD and a liver biopsy showed a chronic lymphocytic infiltrate particularly in the biliary canaliculi, with single cell apoptosis of periportal hepatocytes and bile duct destruction, suggestive of severe GVHD. A diagnosis of grade IV GVHD of the gut and liver, together with marrow aplasia secondary to donor lymphocyte infusion (DLI), was made.
He was treated with intravenous methylprednisolone initially at a dose of 2 mg/kg, subsequently increased to 4 mg/kg. Although his rash and vomiting settled, his lower GI symptoms continued, with episodic cramping abdominal pain and diarrhoea, intermittent melaena and progressive jaundice. In view of the steroid-refractory nature of his GVHD, he was started on Campath 1G 0.2 mg/kg i.v. for 8 days and i.v. cyclosporin, continuing on methylprednisolone 4 mg/kg. On this regimen his diarrhoea improved, his hepatomegaly reduced, the ALT normalised to 52 U/l, and his bilirubin stabilised at around 400 m.
His subsequent course was complicated by a major intraperitoneal bleed 6 days following his liver biopsy, from which he was resuscitated with conservative measures. Shortly after stopping Campath therapy his liver function deteriorated again (bilirubin 603 m, ALT 173 U/l), he was therefore given a pulse of high-dose methylprednisolone (30 mg/kg per day) for 2 days, tailed to 4 mg/kg over a further 5 days, and was started on mycophenolate mofetil. On this regimen his liver decreased in size and his liver function stabilised, although he continued to have abdominal pain and small amounts of diarrhoea/melaena. He remained afebrile throughout this period, and his blood counts gradually improved, suggesting recovery from his aplasia. XY FISH studies at that time showed a marked increase in donor contribution to haemopoiesis, with 100% donor neutrophils and 95% donor mononuclear cells, although the patient remained positive for the BCR-ABL translocation at low level.
Unfortunately, when steroids were tailed to 4 mg/kg once again there was a progressive deterioration in liver function (bilirubin 895 m, ALP 254 U/l, ALT 221 U/l). Finally, 12 weeks after donor lymphocyte infusion, the patient developed a febrile illness associated with bilateral complex partial seizures and subsequent encephalopathy. MRI of his brain showed multiple poorly enhancing lesions in the grey matter of the cerebral hemispheres, cerebellum and the brain stem, consistent with an intracerebral infection, and analysis of the CSF showed a raised protein, though no pleiocytosis. EBV was demonstrated by PCR in both the blood and CSF, and a presumptive diagnosis of EBV encephalitis was made. Despite specific anti-viral as well as broad spectrum anti-bacterial/anti-fungal/antiToxoplasma therapy, the patient's condition continued to decline and he died shortly afterwards.
Discussion
We have described the case of a 10-year-old boy with molecular relapse of CML following unrelated donor BMT who developed fatal grade 4 acute GVHD of the gut and liver following one antigen-mismatched DLI. DLI is an effective therapy for CML in relapse after allogeneic BMT 4, 7 with response rates between 91% and 64% in molecular/cytogenetic or chronic phase haematological relapses (reviewed by Dazzi et al 8 ) . Initial studies however, demonstrated that this beneficial effect was often associated with GVHD, leading to the development of escalating dose protocols, 6, 9 which appear to give a much lower incidence of GVHD without compromising therapeutic efficiency in the HLA-matched BMT setting. In our patient, in view of the one antigen HLA-A locus mismatch, we used a lowdose of donor lymphocytes (10 6 CD3 positive cells/kg), equivalent to the lowest dose of the escalating dose protocol of Dazzi et al. 6 This dose was chosen because in the study of McKinnon et al 9 no patient developed GVHD after receiving DLI doses of 5 ϫ 10 6 CD3-positive cells/kg or less. Despite this however, our patient developed refractory GVHD within a month of DLI.
In our patient, GVHD post DLI could be due to (a) donor T cell recognition of host minor histocompatibility antigens expressed on non-haemopoietic tissues, 10 in particular H-Y antigens, in view of the sex mismatch between patient and donor; or (b) donor alloreactivity against the mismatched host HLA-A locus or cryptic molecular mismatches at other loci. T cells directed against minor histocompatibility antigens are present at very low frequency in normal unsensitized individuals. 11 In contrast, alloreactive cells, recognising either allo-HLA molecules themselves or in association with bound peptide epitopes are much more frequent. 12 In our patient therefore, given the pace and severity of GVHD, with a dose of lymphocytes not generally associated with this complication, it is likely that the GVHD observed reflected allorecognition of the A68 molecule on the patient tissues by donor T cells.
There have been few published reports of DLI in the HLA-mismatched setting. Wu et al 13 describe a patient with CML and mixed chimerism following a two-antigen mismatched non-myeloablative PBSCT who was converted to full donor chimerism after DLI at a dose of 5 ϫ 10 7 /kg, with no acute and limited chronic GVHD. In the study of Kawano et al, 14 two out of four patients who received DLI (total mononuclear cell doses between 10 6 /kg to 10 8 /kg) following HLA-mismatched CD34-selected peripheral blood stem cell transplants (PBSCT) developed grade 4 GVHD and all died. Kato et al 15 have described a case of DLI following haplo-identical PBSCT for CML in myeloid blast crisis, but the patient died from relapse too early after DLI to assess for GVHD. Despite this limited experience, overall, as expected, there appears to be a high incidence of severe GVHD following mismatched DLI. What then can be done to prevent this? Clearly, in the HLA-mismatched setting, DLI should be avoided if a viable alternative exists. In our case, in retrospect, treatment with STI 571 might have been a reasonable option. If DLI is felt to be appropriate, three potential strategies currently exist to limit toxicity from GVHD. Firstly, DLI could be given in an escalating dose protocol, but given the high precursor frequency of alloreactive T cells, starting with a much lower dose than the protocols used in the HLA-matched setting. In haplo-identical PBSCT T cell doses of approximately 10 4 /kg have been given with the graft, with a low incidence of GVHD despite limited or no prophylaxis, 2, 3 so that this might represent a reasonable starting dose for HLA-mismatched DLI. However such alloreactive cells are unlikely to show haemopoietic specificity. A more elegant approach may be to adoptively transfer allorestricted cytotoxic T cells directed against haemopoietic-specific epitopes, eg from the WT-1 protein, presented by the host MHC class 1 molecules. 16 Alternatively, standard doses of DLI, which have been transduced with a suicide gene such as HSV-TK 17, 18 could be given, so that if GVHD developed, the response could be aborted with ganciclovir treatment. All of of these strategies, however, remain experimental and currently the use of DLI in the HLAmismatched setting should be avoided if at all possible.
